All In Biotech

Drug Trial Radar · NCT01841762

Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument

A Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument

Last checked: Nov 19, 2026Latest source record: Feb 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

284

Actual

Start

Apr 1, 2013

Primary completion

Nov 1, 2015

Study completion Nov 1, 2015

Sponsor

Lead sponsor
ActelionJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Apr 29, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

SYMPHONY is prospective, multi-center, open-label, single-arm, Phase 3b psychometric validation study of the PAH-SYMPACT, a new quality of life questionnaire for patients with pulmonary arterial hypertension. Patients will be in the study for 5 1/2 months, 4 months of which they will receive macitentan, 10 mg, once daily. The primary objectives are to demonstrate the final content validity of the PAH SYMPACT instrument, to demonstrate the psychometric characteristics of reliability and construct validity of the PAH-SYMPACT instrument, and to demonstrate the ability of the PAH SYMPACT instrument to detect change. The secondary objective is to assess the safety of macitentan in patients with pulmonary arterial hypertension. The exploratory objective is to explore the effects of macitentan on PAH symptoms and their impact (as measured by the PAH-SYMPACT) in patients with pulmonary arterial hypertension.

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • MacitentanDrug

    Macitentan tablet, dose of 10 mg, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Development and Refinement of the Patient-reported Outcome Measure of Symptoms and Their Impact in PAH (the PAH-SYMPACT)Time frame: From Screening Visit (Day -14) to End of Treatment (EOT) Visit (Visit 4, Week 16)
  2. Validation of the Patient-reported Outcome Measure of Symptoms and Their Impact in PAH (the PAH-SYMPACT), With Reliability Assessed Via Test-retest Reliability.Time frame: From ePRO period 1 (Days -14 to -8) to ePRO period 2 (Days -7 to -1) in screening period.
  3. Validation of the Patient-reported Outcome Measure of Symptoms and Their Impact in PAH (the PAH-SYMPACT), Assessing Internal Consistency Reliability.Time frame: From ePRO period 1 (Days -14 to -8) to ePRO period 2 (Days -7 to -1) in screening period.

Locations

81 sites in 1 country. Site status is shown where the registry gives one.

  • Cardiovascular Associates of the Southeast, LLC

    Birmingham, Alabama

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Pulmonary Associates, PA

    Phoenix, Arizona

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • Cedars-Sinai Medical Center

    Beverly Hills, California

  • UCSF Fresno

    Fresno, California

  • UCSD Medical Center, Pulmonary Department

    La Jolla, California

  • VAGLAHS, VA Greater LA Healthcare System

    Los Angeles, California

  • University of California Los Angeles

    Los Angeles, California

  • University of California San Francisco Medical Center

    San Francisco, California

  • Stanford University

    Stanford, California

  • Los Angeles Biomedical Research Institute

    Torrance, California

  • University of Colorado

    Aurora, Colorado

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Medstar Washington Hospital Center

    Washington D.C., District of Columbia

  • Bay Area Cardiology Associates, P.A.

    Brandon, Florida

  • University of Florida Academic Health Center

    Gainesville, Florida

  • University of Florida College of Medicine, Jacksonville

    Jacksonville, Florida

  • Mayo Clinic

    Jacksonville, Florida

  • Cleveland Clinic Florida

    Weston, Florida

  • Georgia Regents University

    Augusta, Georgia

  • Georgia Clinical Research

    Austell, Georgia

  • Northwestern University

    Chicago, Illinois

  • University of Chicago Medical

    Chicago, Illinois

  • Advocate Health and Hospitals Corporation

    Oakbrook Terrace, Illinois

  • Chest Infectious Diseases and Critical Care Associates, PC

    Des Moines, Iowa

  • University of Iowa Hospitals & Clinics

    Iowa City, Iowa

  • Iowa City Heart Center

    Iowa City, Iowa

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Veritas Clinical Specialties

    Topeka, Kansas

  • Kentuckiana Pulmonary Associates

    Louisville, Kentucky

  • University of Louisville

    Louisville, Kentucky

  • University of Maryland Medical Center

    Baltimore, Maryland

  • Johns Hopkins University

    Baltimore, Maryland

  • Tufts Medical Center

    Boston, Massachusetts

  • Boston University Medical Center

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Beaumont Hospital

    Troy, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Midwest Pulmonary Consultants

    Kansas City, Missouri

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.